Display Settings:

Format

Send to:

Choose Destination
    Nat Rev Immunol. 2007 Mar;7(3):191-201. Epub 2007 Feb 9.

    PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?

    Source

    Merck Serono International S.A., 9 Chemin des Mines, 1211 Geneva, Switzerland. christian.rommel@merckserono.net

    Abstract

    Dysregulated signal transduction in innate and adaptive immune cells is known to be associated with the development of various autoimmune and inflammatory diseases. Consequently, targeting intracellular signalling of the pro-inflammatory cytokine network heralds hope for the next generation of anti-inflammatory drugs. Phosphoinositide 3-kinases (PI3Ks) generate lipid-based second messengers that control an array of intracellular signalling pathways that are known to have important roles in leukocytes. In light of the recent progress in the development of selective PI3K inhibitors, and the beneficial effects of these inhibitors in models of acute and chronic inflammatory disorders, we discuss the therapeutic potential of blocking PI3K isoforms for the treatment of rheumatoid arthritis and other immune-mediated diseases.

    PMID:
    17290298
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk